{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:01Z","timestamp":1793383741605,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T02:18:44Z","timestamp":1759285124000},"page":"1043-1052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-867X","authenticated-orcid":false,"given":"Nishit B.","family":"Modi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje","family":"Darpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.09.002_bib0001","first-page":"3199","article-title":"Iron homeostasis governs erythroid phenotype in polycythemia vera","volume":"141","author":"Benett","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0002","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.002_sbref0004","series-title":"Myeloproliferative Neoplasms. Guidelines for Patients. National Comprehensive Cancer Network","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0005","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0006","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0007","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.90189","article-title":"Normal and dysregulated crosstalk between iron metabolism and erythropoiesis","volume":"12","author":"Ginzburg","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0008","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0009","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/asheducation-2011.1.538","article-title":"The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders","volume":"2011","author":"Ganz","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0010","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa2308809","article-title":"Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera","volume":"390","author":"Kremyanskaya","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.09.002_bib0011","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood-2023-178253","article-title":"Durability of hematocrit control in polycythemia vera with the first-in-class hepcidin mimetic rusfertide: two-year follow up results from the Revive study","volume":"142","author":"Ritchie","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0012","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S2468-1253(23)00250-9","article-title":"Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial","volume":"8","author":"Kowdley","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0013","unstructured":"International Conference on Harmonization. ICH Guideline E14. 2005. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Accessed January 24, 2025."},{"key":"10.1016\/j.clinthera.2025.09.002_bib0014","unstructured":"Food and Drug Administration. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs\u2014questions and answers (R3) guidance for industry. 2017. https:\/\/www.fda.gov\/media\/71379\/download. Accessed January 24, 2025."},{"key":"10.1016\/j.clinthera.2025.09.002_bib0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2008.33","article-title":"The effect of moxifloxacin on QTc and implications for the design of thorough QT studies","volume":"84","author":"Bloomfield","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0091270007307881","article-title":"Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review","volume":"48","author":"Garnett","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0017","first-page":"401","article-title":"Improving the precision of QT measurements","volume":"18","author":"Darpo","year":"2011","journal-title":"Cardiol J"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0018","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bcp.12068","article-title":"Early QT assessment\u2013how can our confidence in the data be improved?","volume":"76","author":"Darpo","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0019","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0091270010381498","article-title":"Population pharmacokinetic and concentration\u2013QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies","volume":"51","author":"Florian","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10543400802020938","article-title":"Statistical issues including design and sample size calculation in thorough QT\/QTc studies","volume":"18","author":"Zhang","year":"2008","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0021","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease","volume":"8","author":"Fridericia","year":"2003","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0022","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mcp.2000.111482","article-title":"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects","volume":"68","author":"D\u00e9molis","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0023","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0091270011398361","article-title":"Re-evaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval","volume":"52","author":"Grosjean","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cpdd.1514","article-title":"Multiple dose pharmacokinetics, pharmacodynamics, safety, and tolerability of subcutaneous rusfertide, a hepcidin-mimetic, in healthy subjects","volume":"14","author":"Modi","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0026","series-title":"Presentation on \u201cNew Advances in the Assessment of Drug-Induced Arrhythmias and the Comprehensive In Vitro Proarrhythmia Assay (CiPA). Cardiac Safety Research Consortium (CSRC) HESI meeting","article-title":"Issues with exposure-response analysis: how we close the gap","author":"Ferber","year":"2018"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0027","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0028","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/1467-9868.00125","article-title":"Smoothing parameter selection in nonparametric regression using an improved Akaike information criterion","volume":"60","author":"Hurvich","year":"1998","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0029","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/ejh.14243","article-title":"Pharmacokinetics, pharmacodynamics and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: a double-blind first-in-human study","volume":"113","author":"Modi","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40268-024-00497-z","article-title":"Pharmacokinetics and pharmacodynamics of rusfertide, a hepcidin mimetic, following subcutaneous administration of a lyophilized powder formulation in healthy volunteers","volume":"24","author":"Modi","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0031","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ahj.2012.02.023","article-title":"Methodologies to characterize the QT\/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects","volume":"163","author":"Garnett","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0032","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jcph.1880","article-title":"The new S7B\/E14 question and answer draft guidance for industry: contents and commentary","volume":"61","author":"Darpo","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.09.002_bib0033","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/cpdd.1003","article-title":"Update on ICH E14\/S7B cardiac safety regulations: the expanded role of preclinical assays and the \u201cdouble-negative\u201d scenario","volume":"10","author":"Lester","year":"2021","journal-title":"Clin Pharm Drug Dev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:56:40Z","timestamp":1774947400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825003091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825003091"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}